Rigel Pharmaceuticals (RIGL) shares ended the last trading session 19.7% higher at $16.35. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 1.6% gain over the past four weeks. Earlier this month, the company enrolled the first patient in a phase Ib/II triplet therapy study, which evaluated its marketed drug Rezlidhia (olutasidenib) in combination with decitabine and venetoclax for the treatment of mutated isocitrate ...